Clinical trials: Unfit, New-diagnosis DLBCL
Double Expressor DLBCL, ELDERLY PEOPLE
Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL
To evaluate the efficacy and safety of Chidamide in combination with lenalidomide and rituximab (CR2) as induction therapy, followed by chidamide maintenance in responding patients with newly diagnosed elderly/unfit…
- Conditions
- Double Expressor DLBCL, ELDERLY PEOPLE, Unfit, New-diagnosis DLBCL
- Trial name
- CR2 (NCT07884708)
- Testing
- Chidamide in combination with Lenalidomide and Rituximab (CR2)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University